OBJECTIVES To present a case of heparin induced thrombocytopenia in a patient treated with enoxaparin. METHODS A case of heparin-induced thrombocytopenia was examinated with a detailed platelet count analysis over the time and with detection of platelets antibodies. RESULTS The detection of platelet antobodies and the recovery of platelet count after cessation of enoxaparin strongly support...

Thromboelastography (TEG) has been used increasingly as an intraoperative hemostasis monitoring device. Low-molecular-weight heparins are given increasingly to reduce the development of antibodies against the heparin–platelet factor 4 complex, and heparinoids are given to patients who have developed the antibody. We studied the effect of unfractionated heparin, a low-molecular-weight heparin (e...

Free full text available from www.ijccm.org A b st ra ct Cerebral venous sinus thrombosis [CVST] is often an infrequent cause of neurological dysfunction resulting in admissions in Intensive care units [ICU]. Because of its myriad presentation it may be under diagnosed. Unfractionated Heparin [UFH] has been advocated in treatment but needs frequent monitoring. We studied the clinical profile of...

Unfractionated heparin (UFH) has been in clinical use for more than half a century. Despite its undoubted contribution to the treatment and prevention of thrombosis, heparin is significantly limited by its variable biochemical composition and unpredictable pharmacokinetics. The situation is compounded by the fact that methods for monitoring heparin do not necessarily reflect its therapeutic eff...

Heparin is the predominant anticoagulant used in cardiac and vascular surgery. Heparin-induced thrombocytopenia (HIT) is one of the most serious and life-threatening adverse drug reactions associated with heparin use. In addition to the development of thrombocytopenia, HIT is associated with a high risk (40-50%) of thrombotic complications. The pathophysiology of HIT is now well understood and ...

Heparin is the most widely used anticoagulant for the prevention and initial treatment of venous thromboembolism, for haemodialysis and cardiopulmonary bypass procedures and, with aspirin, for the management of acute coronary syndromes. In venous thrombosis and coronary disease low molecular weight heparins (LMWHs) have been demonstrated to be at least as effective and safe as unfractionated he...

Venous thromboembolism (VTE) is the cause of significant morbidity and mortality and may lead to other complications, including recurrent VTE and long-term postthrombotic syndrome. Venous thromboembolism represents a huge health economic burden of nearly 500 million dollars/year in the United States. Without adequate prophylaxis, patients undergoing major orthopedic surgery are at high risk of ...

The question ‘What is the best prophylaxis for venous thromboembolism in the critically ill?’ is clinically relevant. The answer is formulated based upon the best available evidence with a focus on pharmacological prophylaxis and symptomatic venous thromboembolism. Four randomized controlled clinical trials with a grade I level of evidence are discussed in detail. Unfractionated heparin is the ...